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ABSTRACT: There is a great demand for the discovery of
new therapeutic molecules that combine the high specificity
and affinity of biologic drugs with the bioavailability and lower
cost of small molecules. Small, natural-product-like peptides
hold great promise in bridging this gap; however, access to
libraries of these compounds has been a limitation. Since
ribosomal peptides may be subjected to in vitro selection
techniques, the generation of extremely large libraries (>1013)
of highly modified macrocyclic peptides may provide a
powerful alternative for the generation and selection of new
useful bioactive molecules. Moreover, the incorporation of many non-proteinogenic amino acids into ribosomal peptides in
conjunction with macrocyclization should enhance the drug-like features of these libraries. Here we show that mRNA-display, a
technique that allows the in vitro selection of peptides, can be applied to the evolution of macrocyclic peptides that contain a
majority of unnatural amino acids. We describe the isolation and characterization of two such unnatural cyclic peptides that bind
the protease thrombin with low nanomolar affinity, and we show that the unnatural residues in these peptides are essential for the
observed high-affinity binding. We demonstrate that the selected peptides are tight-binding inhibitors of thrombin, with Ki
app
values in the low nanomolar range. The ability to evolve highly modified macrocyclic peptides in the laboratory is the first crucial
step toward the facile generation of useful molecular reagents and therapeutic lead molecules that combine the advantageous
features of biologics with those of small-molecule drugs.
■ INTRODUCTION
Two classes of molecules dominate drug discovery efforts:
small molecules and biologics.
1 Therapeutic biological macro-
molecules have become one of the most successful classes of
therapeutics due to their high affinity and specificity toward a
specific antigen and their predictable nature in the clinic.
2
However, the high cost and complexity of production of
biologics might be prohibitive for their use in the treatments of
chronic diseases.
3 In addition, since biologics cannot penetrate
cells, ∼90% of drug targets are not accessible for targeting.
1
Most small molecules that satisfy Lipinski’s rule of five
4 are able
to penetrate cells and can be chemically synthesized in large
amounts. However, small molecules have much higher attrition
rates in the clinic than biologic drugs, and only ∼25% of
recently approved small-molecule drugs can be defined as new
molecular entities, compared to ∼90% of biologic drugs.
5 In
addition, since ∼10% of proteins encoded in the genome are
estimated to be amenable to small-molecule targeting and
another 10% by biologic drugs, 80% of proteins are currently
termed as “undruggable”.
1,6,7 Thus, it is clear that new classes of
molecules are urgently needed for drug discovery.
Small constrained peptides comprise a large class of
molecules that could combine the high specificity of biologic
drugs with the bioavailability of small molecules. Organisms
have evolved the ability to produce an arsenal of macrocyclic
peptides such as lantibiotics, peptide hormones, toxins, and
non-ribosomal peptides (NRPs) that show a wide range of
biological activities as a result of their ability to bind and
interact with a diverse range of targets.
8 Importantly, these
macrocyclic peptides rarely function by binding to the active
site of an enzyme, but rather modulate key macromolecular
interactions that are difficult to target using small molecules.
9 In
addition, synthetic structurally constrained peptides (stapled-
helices) have had great success in combining the surface-
recognition properties of biologics with the bioavailability and
synthetic manipulability of small molecules.
10,11 The common
feature of these molecules is the structural constraint afforded
by cyclization, often in combination with the presence of
unnatural amino acids with side-chain and backbone
modifications.
However, the isolation, screening, identification, and
preparative synthesis of many naturally occurring macrocyclic
peptides has been very challenging, and thus this structural class
of molecules has been underexploited.
9 Although the chemical
diversity of building blocks that can be used for the synthesis of
peptide libraries is large, synthetic peptide libraries tend to be
small, thus decreasing the chance of finding potent and
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lators of protein−protein interactions and have shown
promising properties. However, a significant amount of
knowledge about the particular protein target is required for
the synthesis and screening of stapled peptides for the desired
activity.
10,11 Ribosomal peptides are amenable to powerful in
vitro selection technologies such as phage, yeast, or mRNA-
display, allowing the screening of trillions of molecules with the
desired properties. However, the poor bioavailability of
proteinogenic peptides has limited their use as therapeutics.
The drug-like properties of ribosomal peptides could be
enhanced by increasing the chemical diversity of the building
blocks in conjunction with macrocyclization of the unnatural
peptides analogous to naturally occurring cyclic peptides. Since
the resulting highly modified peptides are templated by mRNA,
in vitro selections could allow isolation of therapeutic lead
molecules from large, unexplored libraries for a wide range of
important biological targets. However, few in vitro selection
experiments have used unnatural amino acids.
12−14 One of the
major challenges in the field is that unnatural amino acids are
often incorporated into peptides very inefficiently, resulting in a
bias against peptides that include them. For this reason, only
selections in which the unnatural amino acid provided a strong
selection advantage (e.g., a biotinylated amino acid with a
streptavidin target, covalent modification) have been successful.
In other cases, none of the surviving peptide sequences
contained the unnatural amino acid.
15 This bias against
unnatural amino acids is magnified when one attempts to
synthesize peptide libraries that contain multiple, different
unnatural amino acids. Thus, for our goal of selecting highly
modified peptides from large, unbiased libraries, we needed a
system that would allow us to carefully adjust experimental
conditions such that sequences containing unnatural amino
acids would not be eliminated from the pool.
We thought that the bias against peptides that contain many
unnatural amino acids might be overcome by combining the
PURE translation system (Protein Synthesis Using Recombi-
nant Elements) with mRNA-display for generating libraries of
highly modified peptides. mRNA-display is a robust and
completely in vitro selection technique that covalently links
individual peptides with their corresponding mRNA, creating
large peptide libraries with 1013 or more members that are
suitable for in vitro selection experiments.
16,17 The PURE
system reconstitutes the ribosomal translational machinery in
vitro from purified components.
18 Recently, several groups,
including ours, have used mRNA-templated peptide synthesis
to incorporate unusual amino acids into peptides for the
generation of highly modified linear and cyclic peptides, using
the PURE translation system.
19−28 We showed that over 50
unnatural amino acids can be incorporated into peptides by the
ribosomal translational machinery. This approach allowed us to
produce peptides containing as many as 13 different unnatural
amino acids using optimized mRNA templates.
22 In addition,
we have shown that the system can be manipulated so that the
mis-incorporations resulting from competition with near-
cognate aminoacyl-tRNAs are minimized,
23 leading to
improved incorporation of up to three N-methyl amino acids
into one peptide. Subsequently, Suga’s group used a modified
PURE system for the in vitro selection and isolation of cyclic N-
methyl peptides with sub-nanomolar binding affinities. In this
system, 5 of 16 codons were reassigned to 4 N-methyl amino
acids and the start codon was reassigned to chloroacetyl-D-
tryptophan using precharged tRNAs and a limited set of natural
amino acids.
29 Here we describe the optimization of a
combined PURE/mRNA-display system that generates the
tRNAs charged with many different unnatural amino acids in
situ. Using this system, we reassign 12 of the 20 natural amino
acids to unnatural amino acids with a diverse set of side-chain
and backbone modifications, to discover highly modified
macrocyclic peptides with antibody-like binding affinities. In
addition we show that these peptides act as potent enzyme
inhibitors. This work lays the foundation for a powerful
platform for the in vitro selection and evolution of drug-like
Figure 1. In vitro selection of macrocyclic peptides using mRNA-display. (A) General scheme for the selection and amplification of cyclic peptides.
The DNA library encodes peptides with 10 random amino acids flanked by two Cys residues. Following transcription and cross-linking of the RNA
to a 3′-puromycin oligonucleotide, the library was translated in a completely reconstituted translation system with either all natural or replacing 12
natural amino acids with 12 unnatural amino acids to form two separate libraries of mRNA-peptide fusions. The 12 unnatural amino acids used are
shown in panel B. Fusions were immobilized on an oligo-dT column and cyclized via bis-alkylation of the Cys residues, reverse transcribed (RT), and
purified on a Ni-NTA resin to yield ∼2 × 1013 cyclic peptides. Each library was incubated separately with biotinylated thrombin in solution.
Complexes were captured on streptavidin beads, and unbound material was washed away. Active mRNA−peptide fusions were eluted with a 2-fold
excess of hirudin to thrombin, followed by RT-PCR amplification to generate the input material for the next round of selection/amplification. (B)
Unnatural amino acids used in the unnatural peptide selection. Differences between the natural and unnatural residues are highlighted in red. The
single-letter code refers to the corresponding natural amino acid that was replaced by the unnatural amino acid, with a subscript for analogue. The
natural amino acids used were C, A, G, S, I, N, Q, and H.
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biologic drugs.
■ RESULTS AND DISCUSSION
For our selection we used a DNA library (Figure 1A) that was
designed for the mRNA-display of short peptides consisting of
10 random amino acids flanked by Cys residues. We chose the
unnatural amino acid building blocks on the basis of the
following criteria: The building blocks had to be compatible
with each other, serve as efficient substrates for only one
aminoacyl-tRNA synthetase (AARS), be translated with high
fidelity and yield using mRNAs transcribed from our DNA
library, and possess interesting functional groups. We decided
not to include any unnatural amino acids that provide a strong
selection (binding) advantage in our library. No previous
selections produced winners from naı̈ve peptide libraries that
contained a majority of unnatural amino acids, and we wanted
to show that our selection platform could yield highly modified
peptides with high binding affinity from such peptide libraries.
Using a set of sequences cloned from our library, we tested
several combinations of amino acid analogues, searching for a
set that resulted in high translational fidelity and good peptide
yields. Initially we observed significant mistranslated and
truncation products and low yields using unnatural amino
acids with our library (Figure 2).
After several iterations of adjusting concentrations of the
amino acid building blocks and eliminating problematic amino
acids, we were able to find 12 unnatural amino acids that met
our criteria and effectively replaced 12 of the natural amino
acids (Figures 1B and 2; Table S1), retaining 8 natural amino
acids for the remaining coding blocks. The 12 unnatural amino
acids display functional groups not found in the standard 20
amino acids, including an alkyne (Ma), a thiazolidine (Pa), two
aryl halides (Ya,F a), an alkene (Ka), two unusual heterocycles
(Ea,W a), and the tert-butyl group (La). The Ra and Ya residues
have altered pKa’s relative to their natural counterparts. Other
unique properties include the blue-shifted fluorescence of Wa
and the metal chelating ability of Da. This set also includes an
α,α-disubstituted amino acid (Va), which would lead to a local
conformational constraint on the peptide backbone. Half of the
unnatural amino acids used to build our library are racemic
mixtures. Although we do not know with certainty, we believe
that incorporation of D-amino acids is unlikely (discussed
further in the SI).
Target specificity and proteolytic stability are important
features of therapeutically active peptides
30,31 and natural
products such as NRPs.
32 These advantageous pharmacological
properties are thought to result in part from peptide cyclization:
the afforded structural rigidity locks the peptide into a target
specific conformation, thereby increasing specificity while also
increasing protease resistance by reducing protease accessible
conformations.
9 We recently showed that peptides containing
unnatural amino acids can be cyclized efficiently using a
previously described bis-alkylation reaction to cross-link two
Cys residues.
20,33 This alkylation chemistry has also been used
in a phage-display selection to afford bicyclic peptides with
target-specific binding.
34 We examined the cyclization of
peptides from our library that were translated with either
natural amino acids or multiple unnatural amino acids.
Incubation of individual pure natural peptides, a pool of
natural peptides, or a pool of unnatural peptides with
dibromoxylene resulted in efficient cyclization (Figure S1).
By applying the same procedure to a library of mRNA-
displayed unnatural peptides (generated by in vitro translation
of mRNAs conjugated to an oligonucleotide with a 3′-
puromycin residue), we were able to generate a library of
∼1013 unique macrocyclic peptides, each containing multiple
unnatural amino acids and displayed on its own mRNA.
Once we were confidant that most, if not all, random
sequence unnatural peptides would be efficiently translated and
cyclized, we proceeded to attempt to isolate target-specific
ligands by in vitro selection from the library. We chose the
protease thrombin as our initial target since RNA, DNA, and
peptide aptamers that bind to this enzyme have been isolated
and would serve as interesting points of comparison.
35−37
Thrombin is part of the blood coagulation cascade, catalyzing
the cleavage of fibrinogen to fibrin, and new thrombin
inhibitors are still being pursued for the prevention and
treatment of thrombosis.
38
Beginning with our unnatural macrocyclic peptide library, we
performed successive rounds of in vitro selection for thrombin
binding followed by amplification by RT-PCR and in vitro
translation (Figure 1A). In order to compare the results of
selection from unnatural and natural peptide libraries, we
performed a parallel selection using the same DNA library to
produce cyclic peptides composed solely of natural amino acids.
Figure 2. Optimizing translation with unnatural amino acids. MALDI-
TOF spectra of in vitro translation reactions with unoptimized and
optimized concentrations of unnatural amino acids. (A) Reaction
directed by mRNA encoding the sequence
MaCVaFaGNRaGTaQPaFaCGSGSLaGHHHHHHRaLa (unnatural
amino acids are labeled with the subscript a) shows several minor
incorrect peaks and a major incorrect peak (×) at 3124.5 Da (most
likely corresponding to −L truncation; exp −127.1 Da, obs −127).
The peak at 3251.5 Da corresponds to the correct product (expected
mass of 3251.4 Da). (B) In vitro translation of the same templates after
optimization of the amino acid concentrations, showing improved
incorporation. (C) Unoptimized in vitro translation reaction directed
by mRNA encoding the sequence
MaCEaFaFaDaKaKaILaAPaCGSGSLaGHHHHHHRaLa shows several
minor undesired peaks and a major incorrect peak (×) at 3249.7 Da
(most likely corresponding to −L truncation). The peak at 3377.9 Da
corresponds to the correct product. (D) In vitro translation of the
same template after optimization of amino acid concentrations,
showing improved incorporation.
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biotinylated thrombin in solution, followed by capture of the
complexes on streptavidin beads. Immobilized complexes were
then washed extensively and selectively eluted with hirudin, a
small protein (65 amino acids) that contains a sulfated Tyr
residue at position 63
39 that contributes its femtomolar
inhibition constant to thrombin.
40 Since we wanted to evolve
novel peptide sequences, we did not use sulfated Tyr in our set
of unusual amino acids, even though it is a substrate for the
translational machinery and has been used with phage-display.
12
After six rounds of selection and amplification, both the natural
and unnatural pools were enriched with thrombin binders
(Figure 3A). We cloned and sequenced the eluted fusions after
the seventh round. The natural peptide selection had converged
on one dominant sequence, but the unnatural peptide selection
yielded a highly diverse set of sequences (Figure S2). In order
to select for peptides with the best possible binding, we
continued the selection for three additional rounds of increased
stringency. We selected for both natural and unnatural peptides
with a very slow off-rate by amplifying only those peptide−
mRNA fusions that remained bound to thrombin after 1 h in
the presence of hirudin and were subsequently eluted during an
overnight incubation with hirudin.
The sequences we obtained after a total of 10 rounds of
selection for the unnatural and natural peptides are shown in
Figure 3B,C. Sequences for the unnatural peptides were
assigned on the basis of the aaRS/tRNA pair that was
responsible for incorporation of the corresponding unnatural
building block into the peptides. The unnatural peptide
selection yielded eight families from which two or more copies
of identical sequences were recovered. The largest family
contained eight copies of a sequence coding for a peptide,
named U1, followed by two other families containing five
copies of peptide sequences. Sequence analysis showed that
∼50% of the amino acids encoded within the random region
are unnatural. We expected the peptides to contain ∼50%
unnatural amino acids, based on the set of unnatural amino
acids and the DNA library we used. These results suggest that
these amino acids are well tolerated and not selected against
during in vitro translation and mRNA display.
The natural cyclic peptide that we selected contains the same
amino acid motif, DPGR, that had been previously identified
and shown to be critical for binding in an independent study
using mRNA-display.
35 As expected, this motif is absent in our
unnatural peptide sequences, since three of the four residues in
this motif were replaced with chemically distinct analogues.
None of the selected natural or unnatural sequences show any
similarity to hirudin. Interestingly, the macrocyclic thrombin
inhibitor Cyclotheonamide A,
41 a natural product, also shares
no similarity to any of our selected cyclic peptides. The fact that
the natural and unnatural sequences are unrelated strongly
suggests that the unnatural amino acids sample a different
functional and chemical space than their natural counterparts.
We chose the two most abundant unnatural (U1 and U2)
and the dominant natural (N1) peptide sequences for further
studies (Figure 3B,C). We translated these sequences as free
peptides (i.e., not linked to their mRNA) and then cyclized and
purified the resulting peptides on Ni-NTA resin (Figures 4A,B
and S3−S5). To determine the mass of the peptides, we
performed high-resolution LC/MS analysis on the cyclized full-
length peptides U1, U2, and N1 (Figures 4B and S4,5). The
observed masses of the cyclic peptides are in excellent
agreement with the calculated values. To confirm the correct
site-specific incorporation of the unnatural amino acids, we
sequenced our two unnatural peptide winners by MS/MS
(Figures 4C and S6). The sequencing unambiguously
demonstrated that each unnatural amino acid was present at
the expected site in the unnatural peptides.
We tested the peptides derived from the natural and
unnatural peptide libraries for target binding. We measured
the affinity of these in vitro translated cyclic peptides, labeled
with 35S-Cys, for thrombin using an equilibrium ultrafiltration
binding assay.
42 Unnatural peptides U1 and U2 bind with Kd =
4.5 and 20, nM respectively, and the natural peptide winner N1
binds with Kd = 1.5 nM (Figures 5 and S7−S9; Table 1). To
test the role of the unnatural residues in target recognition, we
substituted the unnatural amino acids with their natural
counterparts. As expected, the peptides lose all measurable
binding activity when the unnatural amino acids are replaced
Figure 3. Selection progress and sequences of selected peptides. (A)
The fraction of 35S-labeled peptide that bound to thrombin and eluted
with hirudin at each round of selection is shown. Starting in round
four, complexes were washed more rigorously, and in round seven the
selection pressure was increased further by only amplifying mRNA−
peptide fusions that remained bound after 1 h of incubation with
hirudin and were subsequently eluted. Red and black bars show the
progress of the unnatural and natural peptide selections, respectively.
(B) Sequences of unnatural peptides after round 10. Unnatural peptide
sequences U2 and U1 are labeled. Unnatural amino acids are
highlighted in red, and the Cys residues used for cyclization are shown
in blue; residues following the second Cys are not shown. (C)
Sequence of the natural peptide winner N1 after round 10.
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1). Thus, the unnatural amino acids are critical for activity and
must result in target recognition through a different set of
interactions than are made by the natural peptide. It is possible
that the higher affinity of the natural peptide N1 reflects
binding at a site on thrombin that has evolved to recognize a
natural peptide ligand. Future biochemical and structural
studies will allow a more detailed comparison of the binding
modes of the natural and unnatural peptides.
Macrocyclization is believed to increase the affinity of
peptides to their target by decreasing the entropic cost of
binding.
31 To determine the effect of macrocyclization of the
peptides on binding affinity, we compared the Kd valus of the
linear and cyclic translated 35S-labeled peptides (Figures S3−
S5). Cyclization of peptides U1, U2, and N1 contributes
significantly to their affinity to thrombin, as demonstrated by an
11−80-fold increase in the Kd values for the linear peptides
relative to the corresponding cyclic peptides (Figures 5, S8, and
S9; Table 1). Interestingly, the affinities of the unnatural
peptides show a larger dependence on cyclization than that of
the natural peptide. Thus, structural constraint is more
important for the activity of the selected unnatural peptides
U1 and U2 than for that of N1, suggesting that the linear
unnatural peptides might be more disordered and less likely to
form well-defined structures than the linear natural peptide.
Next, we determined the ability of the selected peptides to
inhibit the enzymatic activity of thrombin. Peptides U1, U2,
and N1 were in vitro translated in the presence of 35S-Cys,
followed by cyclization and purification. Thrombin was
preincubated with varying concentrations of macrocycles U1,
U2, or N1 (as determined by scintillation counting) and
assayed for enzymatic activity using a small, internally quenched
FRET substrate of thrombin (AnaSpec). Inhibition is observed
for all macrocyclic peptides. Fitting of the data to the Morrison
equation for tight-binding inhibitors yielded Ki
app values of 23,
Figure 4. Verification of sequence of unnatural peptide U1. (A) Cyclization of unnatural peptide U1. Unnatural amino acids are shown in red. Cys
residues used for cyclization are shown in blue. (B) LC-MS confirms formation of full-length cyclic unnatural peptide U1 (calcd [M]4+ m/z =
791.62226 (4.4 ppm), [M]5+ m/z = 633.49937 (0.9 ppm), [M]6+ m/z = 528.08411 (0.5 ppm) (A.U., arbitrary units). (C) Peptide lacking the His6-
tag was translated and the two Cys residues modified with iodoacetamide to prevent disulfide formation. LC-MS/MS analysis confirms site-specific
incorporation of each unnatural amino acid into peptide U1 in the correct order. Predicted and observed ions are summarized in Tables S3−S5.
Figure 5. Binding of selection winners to thrombin. Binding curves for
unnatural cyclic peptide U1 (closed circles), unnatural linear peptide
U1 (open circles), and cyclic peptide U1 translated with natural amino
acids (closed triangles). 35S-Cys-labeled peptides were incubated with
varying concentrations of thrombin for 1 h. Cyclization via disulfide
formation of the linear unnatural peptide U1 was prevented by the
addition of 0.2 mM TCEP in the binding buffer. Bound and free
peptides were separated using a 30 kDa MW cutoff spin-filter. The
fraction of bound peptide fa (see Materials and Methods) was plotted
against the concentration of thrombin and fit to a simple hyperbola to
obtain the Kd values.
Table 1. Summary of Binding and Inhibition Constants of
Selection Winners and Variants to Thrombin
Kd (nM) Ki
app (nM)
peptide cyclic linear natural cyclic
U1 4.5 ± 0.8 350 ± 270 >500 23 ± 3.3
U2 20 ± 7 >500 >500 35 ± 19
N1 1.5 ± 0.2 17 ± 8 N.A. 6.3 ± 3.8
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(Figure 6; Table 1). These values are in excellent agreement
with the observed Kd values. Although we did not select for
enzyme inhibitors, we obtained potent tight-binding inhibitors
of thrombin. It will be interesting to determine where these
inhibitors bind to inhibit enzymatic activity. Since we expect
target recognition of the unnatural peptides through a different
set of interactions than are made by the natural peptide, the
mechanism of enzymatic inhibition also might be distinct.
■ CONCLUSIONS
Our work shows that in vitro selections can be used to evolve
small macrocyclic unnatural peptides that bind with high
affinity to a target and inhibit its enzymatic activity from very
large unbiased libraries (1013). Our work, in conjunction with
the recently published selection of N-methyl amino acid
containing cyclic peptides, shows that selections of natural-
product-like molecules that contain a wide range of side-chain
and backbone modifications should be feasible. An important
advantage of our system is that very large libraries of bioactive
molecules can be constructed and screened in the laboratory
with basic molecular biology and biochemistry tools. Since
these selections are affinity based, they require only small
amounts of material and moderate amount of labor. This is in
stark contrast to traditional small-molecule high-throughput
screening methods where only small libraries can be
constructed and screened. In addition, most laboratories are
restricted to commercially available libraries, sampling a rather
narrow chemical space. To our knowledge, the only other
successful approach for the discovery of novel bioactive
macrocycles using in vitro selections used DNA-encoded
libraries,
43 from which the most potent isolated molecule was
found to have a Ki of 700 nM. Again, this method is not
available to most laboratories since these libraries have to be
chemically synthesized. In addition, since these DNA encoded
libraries are chemically synthesized, they tend to be small (1.4
× 104).
Based on the known activities of structurally constrained
peptides such as NRPs, it is likely that such highly modified
peptides will be useful in modulating challenging targets that
have been recalcitrant to small-molecule inhibition or
activation. A major question for the future is whether the
structural and functional diversity offered by unnatural amino
acids will ultimately allow for sufficient bioavailability of cyclic
unnatural peptides to enable therapeutic applications. The
known resistance of cyclic peptides to protease digestion may
be further enhanced by the replacement of natural amino acids
with analogues that decrease recognition by proteases, while
backbone modifications such as N-methylation may enhance
cell permeability. Future advances in the technology of
unnatural peptide synthesis by ribosomal translation will lead
to the ability to incorporate a much larger array of
modifications into peptides. The flexizyme system,
44 a highly
evolved ribozyme that is used to charge unnatural amino acids
onto tRNAs, has already facilitated the incorporation of α-
hydroxy acids, N-methyl amino acids, and other unusual
building blocks into peptides by ribosomal peptide syn-
thesis.
25,45 Ultimately the engineering of EF-Tu and the
ribosome itself
46 may allow the direct incorporation of even
more diverse building blocks into modified peptides by in vitro
translation. In the meantime, many modifications can be
introduced by post-translational derivatization. For example,
peptides can be simultaneously cyclized and labeled with a wide
range of Cys-alkylating agents to attach fluorophores, lipids,
and other small molecules.
47 Amino acids with electrophilic
side-chain warheads such as dehydroalanine, which is often
found in NRPs, can be used to covalently attach new functional
groups or to cyclize the peptide in a manner analogous to
lantibiotic biosynthesis.
20,48−50 Peptides containing alkynes and
azides can also be cyclized or modified by the incorporation of
virtually any functional group,
19,46,51 such as pegylation, which
results in lower renal clearance, superior stability in vivo, and
lower immunogenicity.
52
As more selections with diverse building blocks are
completed, it may become possible to discern whether certain
amino acids are generally beneficial for the directed evolution of
drug-like molecules, or if the choice of amino acids should be
target specific. Ultimately it may be possible to design libraries
of unnatural cyclic peptides that are predisposed to favor oral
availability, good pharmacokinetics, and low toxicity, so that
molecules with good drug-like properties are already present in
the starting pool. If this potential can be realized, the ability to
evolve macrocyclic peptide libraries will be a powerful method
for the discovery of novel therapeutics.
■ MATERIALS AND METHODS
Unnatural Amino Acid Optimization on mRNA Library. The
PURE system and standard translation assays were previously
described, and detailed methods can be found in the Supporting
Information (SI).
19,22 Based on previous work in which we identified
amino acid analogues that could be incorporated into peptides,
22 we
selected a set of 12 unnatural amino acids along with 8 natural amino
acids for optimization. Two templates from the library (see Figure 2)
were chosen for the optimization reactions. The concentrations of the
unnatural amino acids were varied and the results analyzed using the
peptide translation assay. Peptide yields were determined by 35S-Cys
incorporation, and purity was assessed by mass spectrometry on a
Applied Biosystems Voyager MALDI-TOF with delayed extraction
operated in the positive mode (Figure 2). The purity of the unnatural
Figure 6. Inhibition of thrombin activity. Inhibition curves for
unnatural cyclic peptide U1 (red), unnatural cyclic peptide U2 (blue),
and natural cyclic peptide N1 (black). Thrombin was preincubated
with varying concentrations of 35S-Cys labeled peptides for 1 h. The
reaction was started by the addition of a 10mer peptide substrate
(AnaSpec), and the increase in fluorescence was monitored for 1 h.
Initial rates were determined, and the fraction of remaining enzymatic
activity was plotted against the concentration of peptide and fit to the
Morrison equation for tight-binding inhibitors to obtain Ki
app. All
experiments were done at least in duplicate.
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the yield of the translated mRNA library improved from 10% of the
natural amino acid translation to 50% after optimization. In particular,
the proline analogue Pa was a translation inhibitor at concentrations
above 20 μM, and the leucine analogue La required addition at a high
concentration (6.6 mM) to prevent premature translation truncation.
Optimized concentrations are summarized in Table S1.
Cyclization of Individual Library Members. Several members
of the naı̈ve library were chosen at random from sequences that had
no stop codons and no cysteines in the random region. In vitro
translated and Ni-NTA purified (see SI) peptides were desalted by
Zip-Tip and eluted with 6 μL of 1:1 CH3CN:0.1% TFA. The resulting
peptides (3 μL) were used in cyclization reactions (10 μL) containing
20 mM NH4CO3 pH 8.6, 200 μM tris-carboxyethylphosphine
(TCEP), 1.1 mM dibromoxylene, and 25% CH3CN. Each reaction
also contained 10 mM TRH-SH Pro (American Peptide Co.) as a
positive control for cyclization and as a MALDI-MS standard. After 60
min, 1 μL of the reaction mixture was mixed with 1 μL of 10 mg/mL
CHCA matrix 1:1 CH3CN:0.1% TFA. This mixture was spotted
directly onto a MALDI plate for MS analysis.
Cyclization of the Peptide Library. In vitro translations were
performed as described above with natural amino acids (250 μL) or
unnatural amino acids (500 μL) using the mRNA CX10C library as a
template. The peptide products were purified using Ni-NTA and
eluted with 50 μL of 1% TFA. After Zip-tip desalting and eluting in 4
μL of 1:1 CH3CN:0.1% TFA, 0.5 μL (natural) or 1 μL (unnatural) of
these solutions were analyzed by MALDI-TOF MS. The Zip-tipped
peptide libraries were added to a reaction mixture containing final
concentrations of 20 mM NH4CO3 pH 8.6, 200 μM TCEP, 1.1 mM
dibromoxylene (Fluka), and 25% CH3CN. After 25 min, the reaction
mixture was combined with CHCA matrix solution 1:9 and analyzed
by MALDI-TOF MS.
mRNA Display: In Vitro Selection and Evolution. Materials
used for mRNA display can be found in the SI. The peptide−mRNA
fusions were produced by translating mRNA photochemically ligated
to a puromycin linker (0.57 μM cross-linked mRNA, 1.14 μM total
mRNA) in 5 or 10 mL standard translation reactions with either
natural or unnatural amino acids respectively for 1 h at 37 C.
19,53
Following the translation reaction, the KCl and Mg(OAc)2
concentrations were adjusted to 550 and 50 mM, incubated an
additional 15 min at room temperature, and then frozen overnight at
−30 °C. The resulting mRNA−puromycin−peptide fusions were
diluted 10-fold for the natural peptides and 5-fold for the unnatural
peptides into oligo(dT) cellulose binding buffer (10 mM EDTA, 1 M
NaCl, 0.5 mM TCEP, 20 mM Tris, pH 8, 0.2% w/v Triton X-100),
and this mixture was incubated with 10 mg mL−1 oligo(dT) cellulose
(New England Biolabs) for 15 min at 4 °C with rotation. The mixture
was transferred into several 20 mL Econo-Pac chromatography
columns (BioRad). The eluate was passed through the columns two
more times, and then each column was washed with 2 × 10 mL of
wash buffer (0.3 M NaCl, 0.5 mM TCEP, 20 mM Tris, pH 8, 0.1% w/
v Triton X-100). The immobilized fusions were then cyclized by the
addition of 3 mL of cyclization buffer (660 mM NaCl, 10 mM Tris pH
8, 3.3 mM dibromoxylene, 0.5 mM TCEP, 33% CH3CN) to each
column. The columns were washed twice with 4 mL of wash buffer
(20 mM Tris pH 8, 300 mM NaCl, 0.5 mM TCEP) and eluted with 8
× 375 μL of water. Fractions with the highest amount of radioactivity
(3−5) were combined, spin-filtered, and ethanol precipitated using 0.1
vol of 3 M KOAc, pH 5.2, 0.002 vol of glycogen (5 mg/mL), and 3 vol
of ethanol. Pellets were resuspended in 800 μL of water and reverse
transcribed in a final volume of 2 mL of RT-mix (0.5 μM RT-primer
5′-TTTTTTTTTTTTTTTGTGATGGTGATGGTGGCCTAAGC-
3′, 0.5 mM dNTPs, 5 μM DTT, 2 U/μL RNaseOUT, 5 U/μL
Superscript III) in RT buffer at 55 °C for 15 min. The reaction mixture
was then diluted with 1.5 mL of denaturing binding buffer (100 mM
NaH2PO4, 10 mM Tris, 6 M guanidinium hydrochloride, 0.2% Triton
X-100, 5 mM BME, pH 8.0) and combined with 1.25 mL of Ni-NTA
beads (bead volume) and an additional 5.5 mL of denaturing binding
buffer in a 20 mL BioRad column. The column was tumbled for 1 h at
4 °C, washed with 2 × 10 mL of wash buffer (100 mM NaH2PO4, 300
mM NaCl, 0.2% Triton X-100, 5 mM BME, pH 8.0), and eluted with
native elution buffer (50 mM NaH2PO4, 300 mM NaCl, 250 mM
imidazole, 0.2% Triton X-100, 5 mM BME, pH 8.0) in 500 μL
fractions. Fractions with the highest amount of fusions (3−6) were
combined and ethanol precipitated with 3 vol of ethanol. The pellets
were resuspended in 1.5 mL of 1× selection buffer (50 mM Tris, pH
7.8, 100 mM NaCl, 4 mM MgCl2, 0.25%Triton X-100) to yield 31
pmol of natural and 39 pmol of unnatural purified mRNA-displayed
peptides, equivalent to 1.9 × 1013 natural and 2.3 × 1013 unnatural
peptides. These were used for the first round of selection.
Next, 200 pmol (23 NIH units) of biotinylated thrombin
(Novagen) was added to the peptide fusions and allowed to bind
for 1 h at room temperature. Complexes were captured on agarose
streptavidin beads (Pierce Ultralink streptavidin beads) for 2.5 min
and washed with 3 × 2 mL of selection buffer. Thrombin-bound
sequences were eluted with 2 mL of selection buffer containing 43
units of hirudin (Sigma) by incubating for 1 h and collecting the flow-
through. The beads were washed 2 more times with 150 μL of buffer.
The flow-through and first wash were combined, yielding 0.74 pmol of
natural and 0.8 pmol of unnatural peptide fusions in 2.15 mL. This
material was diluted 2-fold with water and PCR amplified, using 19.8
μL of fusions in each 100 μL PCR reaction. PCR reactions were
chloroform phenol extracted, concentrated with 1-butanol, and ethanol
precipitated using 0.1 vol of 3 M KOAc, 2 vol of ethanol, and 0.001 vol
of glycogen (5 mg/mL). The pellets were dissolved in 1× transcription
buffer to give a final concentration of ∼1.5 mg/mL of PCR product.
T7 transcription reactions (0.5 mL) were set up overnight at 37 °C
with a final concentration of 0.6 mg/mL PCR product. Transcription
reactions were treated with 50 units of turbo DNase (Ambion) for 15
min at 37 °C, followed by gel purification on an 8% polyacrylamide
gel. Purified RNA was processed as described above for the
preparation of mRNA-displayed peptides for the next round of
selection and amplification.
Every round was assayed by scintillation counting of the 35S-
cysteine-labeled peptides to measure the efficiencies of the various
steps. These data were then used to determine the number of purified
individual peptide sequences introduced into the round 1 selection
and subsequent rounds. This procedure was repeated for 10 rounds
except for the following changes: in round 2 and in all subsequent
rounds the volume of the translation reaction was 0.25 mL for the
natural and 0.5 mL for the unnatural peptide selection. Reactions and
purifications were scaled accordingly. Magnetic beads (Dynabeads M-
280 Streptavidin, Invitrogen) were used for streptavidin capture of
complexes. Starting in round 4 complexes were washed five times, and
in round 7 the selection pressure was increased further by only
amplifying mRNA−peptide fusions that remained bound to thrombin
after 1 h of incubation with hirudin and were subsequently eluted
during an overnight incubation with additional hirudin.
To analyze the results of the selection, cDNAs were cloned into the
pCR-TOPO vector (TOPO TA Cloning, Invitrogen). Colonies were
screened using X-gal and sent out to SeqWright for plasmid isolation
and sequencing. To generate peptides from individual clones, plasmids
(isolated from SeqWright) were amplified with primers CX10 FWD
and CX10 REV and the PCR products used for T7 in vitro
transcription. The resulting mRNAs were gel purified and used in
translation reactions.
Sequence Analysis. For DNA and peptide sequence alignments,
Jalview was used.
54,55 Unnatural amino acids were assigned on the
basis of the tRNA/aaRS pairs responsible for their incorporation into
peptides.
Ribosomal Synthesis, Cyclization and Purification of
Selection Winners, and LC-MS Analysis. Sequences were amplified
from plasmids using PCR primers CX10 FWD and CX10 REV, the
PCR product used for T7 transcription, and the resulting mRNAs gel
purified. Translation reactions were set up as above, with minor
modifications as described in the SI. Peptides were cyclized on the Ni-
NTA resin in cyclization buffer (20 mM Tris pH 8.0, 100 mM NaCl,
0.2 mM TCEP, 5 mM dibromoxylene, 50% CH3CN) for 30 min at 25
°C and eluted with a 1:1 mixture of 0.1% TFA and CH3CN in
fractions. Fractions with the highest amount of peptide were
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Peptides were analyzed by MALDI-TOF-MS, and spectra were
calibrated using P14R (1532.8582 Da) and insulin B chain
(3493.6513 Da) as the internal standards (Sigma).
For high-resolution MS analysis, the peptide solution was
concentrated in a YM-3 spin-filter to ∼10 μL. The samples were
reconstituted in 0.1% formic acid (FA), 0.2% CH3CN, and 10 mM
EDTA to give a final volume of 40 μL. Peptides were analyzed by LC-
MS on a 6520 Accurate-Mass Q-TOF LC/MS (Agilent) using a 2.1
mm × 100 mm, 3.5-μm ZORBAX 300SB-C18 column (Agilent).
Samples were injected at 200 μL/min and eluted with a 10 min
gradient of 2−100% CH3CN, 0.1% FA at 0.6 mL min−1. The mass
spectrometer was operated in positive mode and calibrated with
reference masses 121.050873 and 922.009798 Da.
Ribosomal Synthesis, Iodoacetamide Modification and
Purification of Selection Winners with His Tag Deletions,
and LC-MS/MS Analysis. Sequences were amplified from the
plasmids containing the full-length transcripts for U2 and U1 using
PCR primers CX10 FWD and the corresponding reverse primer for
the His deletion (U1-HisR, 5′-CTACTAGCCTAAGCTACCG-
GAGCCGCATCC-3′; U2-HisR, 5′-CTACTAGCCTAAGCGACCG-
GAGCCGC-3′). The PCR product was gel purified and used for T7
transcription. The resulting mRNAs were gel purified and used in
subsequent translation reactions. Translations were set up as before
and purified with minor modifications as described in the SI. Cys
residues were modified with iodoacetamide, purified, and analyzed by
LC-MS/MS. Samples were run as described above. The mass
spectrometer was operated in positive mode, and ions were selected
for MS/MS.
Kd Determination of Translated Peptides. Kd values for




app Determination of Translated Peptides. Ki
app values for the
inhibition of thrombin by the selected peptides were determined using
a fluorescence-based assay (AnaSpec) as described in the SI.
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